Literature DB >> 11493988

ret/PTC-1 Activation in Hashimoto Thyroiditis.

O. M. Sheils1, J.J. O'eary, V. Uhlmann, K. Lättich, E. C. Sweeney.   

Abstract

Activation of ret/PTC-1 has been documented in a minority of papillary thyroid carcinomas (PTC). In a recent study, the authors' group detected the presence of ret/PTC-1 in association with a background of florid lymphocytic thyroiditis (LT) in 58% of cases of PTC studied, which prompted them to examine the incidence of RET/PTC-1 expression in 27 examples of various forms of nonlymphomatous lymphoid infiltration of the thyroid by using TaqMan RT-PCR. Overall, 21 cases (78%) were found to express the chimeric transcript of ret/PTC-1. Eighteen cases of Hashimoto thyroiditis were positive (95%), and, of these, three had concomitant PTC while the remainder had no histologic evidence of associated malignancy. Three cases of lymphocytic thyroiditis demonstrated activated ret/PTC-1 (43%), two having associated PTC. These data suggest either that ret/PTC-1 is an indicator of follicular thyroid cell activation or that ret/PTC-1 activation is an early event in malignant transformation. If the latter is the case, it may be that, in a defined subset of the cell population, ret/PTC-1 activation elicits an autoimmune response, which, while possibly curtailing the development of PTC in the majority of cases, results in destruction of the thyroid parenchyma. Int J Surg Pathol 8(3):185-189, 2000

Entities:  

Year:  2000        PMID: 11493988     DOI: 10.1177/106689690000800305

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  32 in total

1.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 2.  Diagnostic criteria in well-differentiated thyroid carcinomas.

Authors:  Elsa Fonseca; Paula Soares; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 3.  Understanding the genotype of follicular thyroid tumors.

Authors:  Jennifer Hunt
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 4.  Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model.

Authors:  H Rubén Harach; Gustavo A Ceballos
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 5.  Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 6.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

7.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.

Authors:  Mosin S Khan; Qurteeba Qadri; Mudasir J Makhdoomi; Muneer A Wani; Aejaz A Malik; Madiha Niyaz; Shariq R Masoodi; Khurshid I Andrabi; Rauf Ahmad; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

8.  Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.

Authors:  Peter M Sadow; Michael C Heinrich; Christopher L Corless; Jonathan A Fletcher; Vânia Nosé
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

9.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

10.  Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases.

Authors:  E Fiore; T Rago; M Scutari; C Ugolini; A Proietti; G Di Coscio; M A Provenzale; P Berti; L Grasso; S Mariotti; A Pinchera; P Vitti
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.